BioIndustry Ethics

TRAMA

This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.

SOMMARIO

Chapter 1: INTRODUCTION Chapter 2: MERCK: STAYING THE COURSE Chapter 3: GENZYME: PUTTING PATIENTS FIRST Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES INDEX

ALTRE INFORMAZIONI

• Condizione: Nuovo
• ISBN: 9780123693709
• Collana: Academic Press
• Dimensioni: 229 x 152 mm
• Formato: Brossura
• Pagine Arabe: 384